Clinical Trials Logo

Clinical Trial Summary

This is an open, randomized, single-center study. The selected patients will be first divided into two major groups according to the type of organ to be transplanted: standard criteria donor (SCD) or extended criteria (ECD) kidney. Then, each group will be randomly allocated to one of the treatments: tacrolimus (TAC) or everolimus (EVL).

All patients received induction therapy with basiliximab (BXB) and maintenance with Mycophenolate Sodium (MYF) and prednisone (P). This study will evaluate as Primary objectives: To characterize the molecular profile of cytokines in kidneys obtained from deceased donors such as "standard" (SCD) and extended criteria (ECD) in biopsies taken before and after transplantation and to evaluate the effect of treatment with everolimus (EVL) in the expression of these molecules. And as Secondaries objectives: To correlate the pattern of cytokines with delayed graft function (DGF), cold ischemia time, episodes of acute rejection and patient and graft survival.


Clinical Trial Description

A total of 80 patients will participate in the study, being distributed into 4 groups of 20 individuals. In a pilot study to assess the interventional effect of the mmediate use of EVL on the cytokine profile of ECD and SCD kidneys, compared to conventional immunosuppressive therapy with TAC, no statistical power analysis could be performed a priori.

Definitions of Extended Criteria Donor and Delayed Graft Function (DGF) Deceased donors aged ≥ 60 years or aged between 50 and 59 years and with at least two of the following risk factors: history of systemic hypertension terminal creatinine levels > 1.5 mg/dL or death by a cerebrovascular accident.

DGF (delayed graft function) is defined as the need for dialysis in the first 7 days after transplantation. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01663805
Study type Interventional
Source Instituto de Urologia e Nefrologia
Contact Mario Abbud, MD.PhD
Phone 551740099191
Email mabbud@terra.com.br
Status Recruiting
Phase Phase 4
Start date January 2012
Completion date June 2015

See also
  Status Clinical Trial Phase
Withdrawn NCT02658162 - A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients Phase 2
Recruiting NCT01513707 - The Effects of Pre-transplant Dialysis Modality on Post-transplant Events N/A
Recruiting NCT02621281 - Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients N/A
Terminated NCT01403389 - A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant Phase 2
Completed NCT02490202 - Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant Phase 2/Phase 3